Compare Stocks: ANTX, IVA, GYRE, and GLAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.36 -1.8%	$5.44	$1.00 ▼ $7.19	$206.04M	-0.99	202,620 shs	156,796 shs
GLAS Glass House Brands	$8.01 -1.1%	$9.75	$5.15 ▼ $13.93	$759.78M	N/A	548,728 shs	767,812 shs
GYRE Gyre Therapeutics	$6.69	$6.49	$5.44 ▼ $9.42	$746M	1.92	65,891 shs	97,765 shs
IVA Inventiva	$3.86 -0.5%	$4.56	$3.35 ▼ $7.98	$805.91M	0.71	936,010 shs	2.63 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	-1.83%	-10.37%	-10.52%	+9.39%	+332.26%
GLAS Glass House Brands	-0.89%	-4.22%	-15.07%	+801,299,900.00%	+801,299,900.00%
GYRE Gyre Therapeutics	0.00%	-6.69%	+0.15%	+10.03%	-15.32%
IVA Inventiva	-0.52%	-17.34%	-16.09%	+9.35%	-27.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.36 -1.8%	$5.44	$1.00 ▼ $7.19	$206.04M	-0.99	202,620 shs	156,796 shs
GLAS Glass House Brands	$8.01 -1.1%	$9.75	$5.15 ▼ $13.93	$759.78M	N/A	548,728 shs	767,812 shs
GYRE Gyre Therapeutics	$6.69	$6.49	$5.44 ▼ $9.42	$746M	1.92	65,891 shs	97,765 shs
IVA Inventiva	$3.86 -0.5%	$4.56	$3.35 ▼ $7.98	$805.91M	0.71	936,010 shs	2.63 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	-1.83%	-10.37%	-10.52%	+9.39%	+332.26%
GLAS Glass House Brands	-0.89%	-4.22%	-15.07%	+801,299,900.00%	+801,299,900.00%
GYRE Gyre Therapeutics	0.00%	-6.69%	+0.15%	+10.03%	-15.32%
IVA Inventiva	-0.52%	-17.34%	-16.09%	+9.35%	-27.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANTX Anthem	2.33	Hold	$9.00	67.91% Upside
GLAS Glass House Brands	2.00	Hold	$16.00	99.68% Upside
GYRE Gyre Therapeutics	1.67	Reduce	$16.00	139.16% Upside
IVA Inventiva	3.10	Buy	$15.75	308.03% Upside

Current Analyst Ratings Breakdown

Latest ANTX, IVA, GYRE, and GLAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/11/2026	GLAS Glass House Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/20/2026	GLAS Glass House Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/14/2026	GLAS Glass House Brands	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	ANTX Anthem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/17/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IVA Inventiva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	GLAS Glass House Brands	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
7/6/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	$116.59M	6.40	$0.22 per share	30.11	$1.48 per share	4.52
IVA Inventiva	$5.07M	158.14	N/A	N/A	($0.22) per share	-17.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
GLAS Glass House Brands	N/A	N/A	N/A	40.07	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	11/6/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)

Latest ANTX, IVA, GYRE, and GLAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q2 2026	IVA Inventiva	-$0.20	N/A	N/A	N/A	$6.35 million	N/A
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANTX Anthem	N/A	14.32	14.32
GLAS Glass House Brands	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	4.26	3.86
IVA Inventiva	N/A	3.16	3.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANTX Anthem	90.47%
GLAS Glass House Brands	N/A
GYRE Gyre Therapeutics	23.99%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
ANTX Anthem	22.61%
GLAS Glass House Brands	N/A
GYRE Gyre Therapeutics	9.50%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
GLAS Glass House Brands	357	93.80 million	N/A	N/A
GYRE Gyre Therapeutics	618	111.51 million	100.92 million	No Data
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable

ANTX, IVA, GYRE, and GLAS Headlines

Recent News About These Companies

Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

4 hours ago | seekingalpha.com

Inventiva To Present Lanifibranor Data Ahead Of Q4 NATiV3 Readout

September 10, 2026 | rttnews.com

Inventiva to Present Multiple Abstracts at Paris MASH 2026

September 8, 2026 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Buy" from Brokerages

September 6, 2026 | marketbeat.com

Inventiva (NASDAQ:IVA) Shares Gap Down - Here's Why

September 4, 2026 | marketbeat.com

Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4

September 3, 2026 | rttnews.com

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

September 2, 2026 | markets.businessinsider.com

Inventiva (NASDAQ:IVA) Shares Gap Up - What's Next?

September 2, 2026 | marketbeat.com

Inventiva names Chris Benecchi as COO ahead of pivotal lanifibranor readout

September 2, 2026 | thepharmaletter.comT

Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout

August 31, 2026 | rttnews.com

Chris Benecchi Named Inventiva’s New Chief Operating Officer

August 31, 2026 | finance.yahoo.com

INVENTIVA: Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finanznachrichten.de

Inventiva names Chris Benecchi as COO

August 31, 2026 | msn.com

Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finance.yahoo.com

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

August 5, 2026 | seekingalpha.com

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

July 30, 2026 | globenewswire.com

Inventiva annonce ses résultats financiers préliminaires pour le premier semestre 2026¹

July 30, 2026 | lesoleil.comL

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

July 29, 2026 | globenewswire.com

Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring

July 15, 2026 | finance.yahoo.com

Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound

July 12, 2026 | finance.yahoo.com

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANTX, IVA, GYRE, and GLAS Company Descriptions

Anthem NASDAQ:ANTX

$5.36 -0.10 (-1.83%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$5.35 -0.01 (-0.19%)

As of 09/15/2026 07:30 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Glass House Brands NYSE:GLAS

$8.01 -0.09 (-1.07%)

Closing price 09/15/2026 03:59 PM Eastern

Extended Trading

$8.04 +0.03 (+0.34%)

As of 09/15/2026 07:57 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Gyre Therapeutics NASDAQ:GYRE

$6.69 0.00 (0.00%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$6.68 -0.01 (-0.07%)

As of 04:54 AM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Inventiva NASDAQ:IVA

$3.86 -0.02 (-0.52%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$3.96 +0.10 (+2.62%)

As of 06:08 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, IVA, GYRE, and GLAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, IVA, GYRE, and GLAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, IVA, GYRE, and GLAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, IVA, GYRE, and GLAS Company Descriptions

Anthem NASDAQ:ANTX

Glass House Brands NYSE:GLAS

Gyre Therapeutics NASDAQ:GYRE

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, IVA, GYRE, and GLAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, IVA, GYRE, and GLAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, IVA, GYRE, and GLAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, IVA, GYRE, and GLAS Company Descriptions

Anthem NASDAQ:ANTX

Glass House Brands NYSE:GLAS

Gyre Therapeutics NASDAQ:GYRE

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools